Clinical Trials · NCT07271251
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 267
- Start date
- Dec 2025
- Locations
- 15 sites, Japan
- Primary endpoint
- Change in glycated haemoglobin (HbA1c).